By directing Asarinin toward OPRM1, it has the potential to inhibit OPRM1, further reducing the synthesis of CGRP and the activation of pain stimulation from other biomarkers implicated in migraine attacks. The gene discussed is OPRM1; the disease is migraine disorder.